[Table_scodeMsg1] 公司研究丨深度报告丨欧林生物（688319.SH） [Table_Title] 破伤风疫苗龙头，金葡菌疫苗全球创新 丨证券研究报告丨 报告要点 [Table_Summary] 破伤风疫苗提供稳定现金流，金葡菌疫苗成为新的增长点。公司目前占据破伤风疫苗市场龙头 地位，在市场空间扩容过程中持续引领行业。随着金葡菌疫苗持续推进，公司新增长引擎出现， 打造可持续的增长曲线。长远来看，公司布局幽门螺旋杆菌疫苗、鲍曼不动杆菌疫苗、铜绿假 单胞菌疫苗等前沿/重磅品种，不断丰富研发管线深度和厚度，构筑深厚护城河。 分析师及联系人 [Table_Author] 彭英骐 张楠 SAC：S0490524030005 SAC：S0490524070006 SFC：BUZ392 %% %% %% %% research.95579.com 1 请阅读最后评级说明和重要声明 2 / 35 %% %% %% %% research.95579.com 2 [Table_scodeMsg2] 欧林生物（688319.SH） cjzqdt11111 [Table_Title2] 破伤风疫苗龙头，金葡菌疫苗全 ...

Group 1 - The core viewpoint of the news is that Oulin Bio experienced a decline in stock price and significant changes in financing activities on January 29, with a net financing outflow of 842.01 million yuan [1] - On January 29, Oulin Bio's financing buy-in amounted to 4.30 million yuan, while the financing repayment was 12.72 million yuan, resulting in a total financing balance of 353 million yuan, which represents 3.56% of its market capitalization [1] - The company has a high financing balance, exceeding the 80th percentile of the past year, indicating elevated financing activity [1] Group 2 - As of September 30, Oulin Bio had 10,200 shareholders, an increase of 56.42% from the previous period, while the average number of circulating shares per person decreased by 36.07% to 39,746 shares [2] - For the period from January to September 2025, Oulin Bio reported revenue of 507 million yuan, a year-on-year increase of 31.11%, and a net profit attributable to shareholders of 47.48 million yuan, reflecting a substantial growth of 1079.36% [2] - Since its A-share listing, Oulin Bio has distributed a total of 15.43 million yuan in dividends [3] Group 3 - Among the top ten circulating shareholders as of September 30, 2025, the fifth largest is XQH Run Mixed A, holding 15.44 million shares, with no change from the previous period [3] - XQH Yi Mixed A ranks seventh with 8.92 million shares, also unchanged, while XQH Commercial Model Mixed (LOF) A is a new entrant in the top ten, holding 4.64 million shares [3]

Core Viewpoint - Watson Bio (300142.SZ) has officially launched 8 self-developed vaccine products (14 specifications) for sale, indicating a strong position in the vaccine market [1] Group 1: Product Offerings - The company has launched the following vaccines: - 13-valent pneumococcal conjugate vaccine (both vial and pre-filled syringe types) - Bivalent HPV vaccine (both vial and pre-filled syringe types) - 23-valent pneumococcal polysaccharide vaccine (both vial and pre-filled syringe types) - Haemophilus influenzae type b conjugate vaccine (both vial and pre-filled syringe types) - Group A and C meningococcal polysaccharide conjugate vaccine (both vial and pre-filled syringe types) - ACYW135 group meningococcal polysaccharide vaccine (both vial and pre-filled syringe types) - Group A and C meningococcal polysaccharide vaccine (vial type) - Adsorbed acellular DTP combined vaccine (vial type) [1] Group 2: Market Position - The company does not currently offer any influenza vaccines among its listed products, which may indicate a focused strategy on other vaccine types [1]

Group 1 - The core point of the article highlights the significant increase in the stock price of Olin Bio, which rose by 8.48% to reach 26.85 CNY per share, with a total market capitalization of 10.893 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with its main revenue sources being 90.99% from adsorbed tetanus vaccine, 4.49% from group A and C meningococcal polysaccharide conjugate vaccine, and 3.99% from type b Haemophilus influenzae conjugate vaccine [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for Huafu Fund, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund holding 600,000 shares, representing 7.56% of the fund's net value, making it the fourth-largest holding [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund has achieved a year-to-date return of 12.99% and a one-year return of 42.45%, ranking 539 out of 9009 and 2957 out of 8164 respectively [2]

Core Viewpoint - Olin Bio (688319.SH), a vaccine company listed on the Sci-Tech Innovation Board, has submitted an application for an H-share public offering and listing on the Hong Kong Stock Exchange to enhance its international strategy and optimize its capital structure [1][2]. Group 1: Company Overview - Founded in 2009, Olin Bio focuses on the research, production, and sales of human vaccines, having commercialized three products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [4]. - The company is pursuing a "dual international development strategy," which includes accelerating global sales and patent transfers while also attracting international patents and talent [4]. Group 2: Product Pipeline and Innovation - Olin Bio is developing a recombinant Staphylococcus aureus vaccine, which is the only one in the world with the most target components and has entered Phase III clinical trials, potentially becoming the first vaccine to combat "superbugs" [4]. - The company is focusing on differentiated competitive strategies in areas such as hospital infection vaccines and innovative vaccines for adults [4]. Group 3: Financial Performance - In the third quarter of 2025, Olin Bio reported a revenue of 507 million yuan, a year-on-year increase of 31.1%, and a net profit attributable to shareholders of 47.48 million yuan, a staggering increase of 1079.4% [5]. - The company has shown steady growth since its listing on the Sci-Tech Innovation Board, with revenues of 547 million yuan, 494 million yuan, and 586 million yuan from 2022 to 2024 [6]. Group 4: Ownership and Market Position - Olin Bio is characterized by a family-controlled structure, with the major shareholder being Shanghai Wushan Biotechnology Co., Ltd., controlled by the father-daughter duo, Fan Shaowen and Fan Fan [8]. - As of January 13, 2025, Olin Bio's market capitalization reached 12.15 billion yuan, and if the Hong Kong listing is successful, it will establish an "A+H" dual-platform capital structure [8]. Group 5: Industry Context - The company is part of a broader trend of Chengdu enterprises accelerating their listings in Hong Kong, with 29 companies from Chengdu already listed on the Hong Kong Stock Exchange [9]. - The ongoing efforts to deepen the connectivity between Chengdu and Hong Kong's capital markets are expected to facilitate more local companies in pursuing the "A+H" strategy [9].

Group 1 - The core point of the article is that Olin Bio has made progress towards its Hong Kong IPO by having its application materials accepted by the China Securities Regulatory Commission [1] - Olin Bio, established in 2009, focuses on the research, production, and sales of human vaccines, with three products commercialized: Tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine [3] - The company is also developing a vaccine for "super bacteria," specifically a recombinant Staphylococcus aureus vaccine, which is the only one in the world with the most target components and has entered Phase III clinical trials [3] Group 2 - Since its listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board in June 2021, Olin Bio achieved profitability in its first year, with revenues of 547 million yuan, 494 million yuan, and 586 million yuan projected for 2022-2024, and net profits of 26.58 million yuan, 11.44 million yuan, and 15.72 million yuan respectively [3] - In the first three quarters of this year, the company reported revenue of 507 million yuan, a year-on-year increase of 31.11%, and a net profit of 47.48 million yuan [3] - The motivation for the Hong Kong listing is to accelerate the company's international strategy and enhance its overseas business development, as well as to improve its overseas financing capabilities and overall competitiveness [3] Group 3 - The backdrop for Olin Bio's Hong Kong listing is the booming IPO market in Hong Kong, which is expected to lead the world in total financing by the Hong Kong Stock Exchange in 2025, with projections of reaching 300 billion HKD in 2026 [4] - Chengdu is deepening its capital market connectivity with Hong Kong, and the pace of local companies seeking to list in Hong Kong is accelerating, with 29 companies from Chengdu already listed [4] - A number of biopharmaceutical, high-tech, and food consumption companies from Chengdu, such as XGIMI Technology and Tianwei Food, are planning to pursue the "A+H" strategy to access broader markets [4]

Group 1 - The core viewpoint of the article is that Olin Bio, a Chengdu-based biotechnology company, has received acceptance for its IPO application on the Hong Kong Stock Exchange, marking a significant step towards its public listing [1] - Olin Bio, established in 2009, focuses on the research, production, and sales of human vaccines, with three products already commercialized: Tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine [1] - The company is also developing a vaccine for "super bacteria," specifically a recombinant Staphylococcus aureus vaccine, which is the only one in the world with the most target components and currently in Phase III clinical trials [1] Group 2 - Since its listing on the Shanghai Stock Exchange in June 2021, Olin Bio achieved profitability in its first year, with projected revenues of 547 million yuan, 494 million yuan, and 586 million yuan for 2022-2024, respectively [1] - The gross profit for the same period is expected to be 500 million yuan, 460 million yuan, and 551 million yuan, with net profits of 26.58 million yuan, 11.44 million yuan, and 15.72 million yuan [1] - In the first three quarters of the previous year, the company reported revenues of 507 million yuan, reflecting a year-on-year growth of 31.11%, with a net profit of 47.48 million yuan [1] Group 3 - The backdrop for Olin Bio's Hong Kong listing is the booming IPO market in Hong Kong, with Deloitte's report indicating that the total financing amount on the Hong Kong Stock Exchange is currently the highest globally [2] - The report forecasts that the Hong Kong IPO market could reach a record financing amount of 300 billion HKD by 2026, driven by the "A+H" listing trend [2] - Chengdu is enhancing its capital market connectivity with Hong Kong, leading to an increase in local companies pursuing listings in Hong Kong, with 29 Chengdu-based companies already listed [2]

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. has signed a market promotion service agreement with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. for the A group C group meningococcal polysaccharide conjugate vaccine, indicating a commitment to long-term cooperation and market expansion [2][4]. Agreement Overview - The agreement allows Keyuan Trading to exclusively promote the AC conjugate vaccine nationwide from 2024 to 2026, with a total promotion task of 4 million doses [4][5]. - A supplementary agreement has been signed to extend the original contract period from December 31, 2026, to December 31, 2029, while maintaining other core terms unchanged [5][6]. Impact on Company Performance - The signing of the agreement is not expected to have a significant impact on the company's current operating performance [3][7]. - The projected sales volume for the AC conjugate vaccine in 2024 is 252,000 doses, but there is uncertainty regarding the actual sales performance due to market conditions [7].

Core Viewpoint - Watson Bio has launched a total of 8 self-developed vaccine products (14 specifications) for sale, focusing on preventing diseases caused by specific pathogens [1] Group 1: Vaccine Products - The company offers the following vaccines: 13-valent pneumonia conjugate vaccine (both vial and pre-filled types), bivalent HPV vaccine (both vial and pre-filled types), 23-valent pneumonia polysaccharide vaccine (both vial and pre-filled types), type b Haemophilus influenzae conjugate vaccine (both vial and pre-filled types), A and C group meningococcal polysaccharide conjugate vaccine (both vial and pre-filled types), ACYW135 group meningococcal polysaccharide vaccine (both vial and pre-filled types), A and C group meningococcal polysaccharide vaccine (vial type), and adsorbed acellular DTP combined vaccine (vial type) [1] Group 2: Marketing and Strategy - The company aims to strengthen product marketing efforts by developing practical strategies and execution measures, enhancing talent development, and leveraging scientific outreach to boost confidence and implementation [1] - The focus will be on improving the coverage and penetration rates of terminal channels to create value for the company and its shareholders [1]

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. is currently facing a legal dispute regarding two core vaccine products, leading to the freezing of some bank accounts by the court, which may impact the company's financial performance and operations [2][3]. Legal Dispute - The company received a lawsuit notification from the Chengdu Intermediate People's Court, where the plaintiff, Wang Jianhua, is demanding a total of 16 million yuan in commissions and an additional 3.2 million yuan in penalties related to vaccine products [2]. - Wang claims to have provided all technical materials for two vaccines and asserts his right to commissions based on a contract signed in 2011 [2]. - Olin Biotechnology disputes the claims, stating that the plaintiff's assertions lack sufficient factual and legal basis and emphasizes its commitment to defend its rights [2]. Financial Impact - The court has frozen 19.2 million yuan from one of the company's non-basic bank accounts, which represents 2.06% of the company's latest audited net assets and 8.57% of the consolidated cash balance [3]. - The company believes that the frozen amount is relatively small and will not significantly affect its daily operations, although the lawsuit pertains to core products [3]. - The financial implications are notable as the frozen amount exceeds the company's net profit for the first half of 2025, highlighting potential pressure on current performance [5]. Product and Revenue Information - Olin Biotechnology has three vaccine products on the market, two of which are related to the technical materials provided by Wang [4]. - In 2024, the Hib conjugate vaccine generated revenue of 23.5 million yuan with a gross margin of 80.9%, while the A/C group meningococcal polysaccharide conjugate vaccine generated 26.42 million yuan with a gross margin of 76.9% [4]. - The company reported a total revenue of 58.89 million yuan in 2024, marking an 18.69% year-on-year increase, with a net profit of 20.76 million yuan, also reflecting an 18.24% increase [4].